OncoMatch/Clinical Trials/NCT06831175
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Is NCT06831175 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Apatinib for adrenal cortical carcinoma.
Treatment: Camrelizumab · Apatinib · mitotane — Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%. For patients with advanced ACC, mitotane alone or combined with traditional chemotherapy was the first-line standard treatment, but its progression-free survival was only about 1 year. The efficacy of mitotane monotherapy is approximately 10% to 30%. FIRM-ACT trial reported an objective response rate (ORR) of 23.2% for etoposide, doxorubicin, cisplatin, and mitotane (EDP-M) chemotherapy regimen. Our phase II study found that PD-1 inhibitor camrelizumab and apatinib showed impressive clinical data in the second-line treatment of relapsed and metastatic ACC patients. The aim of this study is to evaluate the efficacy and safety of PD-1 inhibitor camrelizumab combined with apatinib and mitotane in advanced ACC, and to explore a new treatment strategy for patients with advanced ACC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies
Cannot have received: immunosuppressive therapy
Prior systemic immunosuppressive therapy
Cannot have received: tyrosine kinase inhibitor
TKI treatment within 2 weeks before the first dose
Lab requirements
Blood counts
Hemoglobin (HB) ≥80g/L; ANC ≥1.5×10^9/L; Platelet (PLT) ≥80×10^9/L
Kidney function
Serum creatinine ≤1.5x ULN or creatinine clearance (CCr)≥60 ml/min
Liver function
Total bilirubin (TBIL) ≤1.5x ULN; ALT and AST ≤2.5x ULN or ≤5x ULN if liver metastases are present
Cardiac function
Cardiac markers and natriuretic peptide (BNP) ≤ULN; QT interval > 500 ms excluded; NYHA class III-IV congestive heart failure excluded
Major organ function within 28 days before treatment, meeting the following criteria: ... see full criteria above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06831175 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify